Mer­ck racks up an­oth­er win in wide-rang­ing PhI­II Keytru­da lung can­cer study, this time as so­lo ther­a­py

Mer­ck $MRK has scored an­oth­er big win in its broad range of piv­otal Keytru­da stud­ies in lung can­cer.

This morn­ing in­ves­ti­ga­tors re­port that KEYNOTE-042

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.